Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

538.70INR
3:56pm IST
Change (% chg)

Rs10.70 (+2.03%)
Prev Close
Rs528.00
Open
Rs529.95
Day's High
Rs540.00
Day's Low
Rs529.30
Volume
457,782
Avg. Vol
471,456
52-wk High
Rs854.50
52-wk Low
Rs493.00

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.08
Market Cap(Mil.): Rs1,266,834.00
Shares Outstanding(Mil.): 2,399.31
Dividend: 3.50
Yield (%): 0.19

Financials

  SUN.BO Industry Sector
P/E (TTM): 18.26 13.51 17.30
EPS (TTM): 28.92 -- --
ROI: 20.08 -7.01 -5.28
ROE: 20.01 -6.49 -4.53

BRIEF-Sun Pharma Industries gets members' nod for scheme of arrangement with Sun Pharma Medisales, Ranbaxy Drugs, others

* Gets members' nod for scheme of arrangement among Sun Pharma Medisales, Ranbaxy Drugs, Gufic Pharma, Vidyut Investments, co Source text - (http://bit.ly/2tQBUuR) Further company coverage:

8:31am IST

BRIEF-Sun Pharma Industries' members approve co's scheme of arrangement with Sun Pharma Medisales, Ranbaxy Drugs, others

* Scheme of arrangement with Sun Pharma Medisales,Ranbaxy Drugs, Gufic Pharma,Vidyut Investments approved by members,unsecured creditors Source text: http://bit.ly/2sOhXZj Further company coverage:

20 Jun 2017

BRIEF-Sun Pharmaceutical Industries says US FDA approval for generic zetia tablets

* Says Sun Pharma announces US FDA approval for generic zetia tablets

13 Jun 2017

BUZZ-India's Sun Pharma plunges to 3-1/2-yr low; Q4 profit falls 14 pct

** Shares of Sun Pharmaceutical Industries Ltd plunge as much as 12.8 pct to 494.85 rupees, to their lowest since Aug 29, 2013

29 May 2017

Sun Pharma says 2018 sales may fall as U.S. market gets tougher

MUMBAI India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers.

27 May 2017

Sun Pharma says 2018 sales may fall as U.S. market gets tougher

MUMBAI India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U.S. sales might fall this year because of pressure on drug prices, signalling tough market conditions in the United States for generic drugmakers.

26 May 2017

UPDATE 1-India's Sun Pharma says 2018 sales may fall as U.S. market gets tougher

* Q4 U.S. sales slide 34 pct (Adds Managing Director comments from conference call)

26 May 2017

BRIEF-India's Sun Pharma says expects to launch psoriasis drug next year

* MD Dilip Shanghvi says needs to execute U.S. business better

26 May 2017

BRIEF-Sun Pharma may have single digit decline in consol revenue for FY 18 vs FY 17 - exec

* Dilip Shanghvi says may have single digit decline in consol revenue for FY 18 versus FY 17

26 May 2017

India's Sun Pharma fourth-quarter profit down 13.6 pct

MUMBAI, May 26 Sun Pharmaceutical Industries Ltd , India's largest drugmaker by sales, reported a 13.6 percent drop in its fourth-quarter profit due to slow sales in the United States.

26 May 2017

More From Around the Web

Earnings vs. Estimates